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Glioblastoma Multiforme (GBM) is an aggressive cancer that originates from astrocytes and 
spreads to spinal cord and other parts of the brain. Increase in replication of glial cells leads to 
advantageous mutations in the tumor. According to the cancer statistics from 2015 about 15,320 
deaths were reported due to GBM. Five-year survival is less than 5% making GBM a dreadful 
form of cancer. Current treatment involves complex invasive surgery, followed by chemotherapy 
and radiation. The goal of this study is to develop a combination therapy to treat GBM using 
Poly (lactic-co-glycolic acid) (PLGA) nanoparticles encapsulated with two drugs namely gefitinib 
and GSK461364, each with a unique target. Gefitinib is a Tyrosine Kinase inhibitor, which 
competes for ATP-binding site of EGFR-TK. GSK461364 is a Polo-like Kinase (PLK-1) inhibitor 
that blocks the G2/M transition in tumor cell cycle. These distinct hydrophobic drugs are tested 
on U-87 MG (human malignant glioma) cell line. PLGA is attached to Polyethylene glycol (PEG), 
which is conjugated to transferrin receptor binding peptide. These transferrin peptides bind to 
transferrin receptors (TfR) or CD71 and enable the entry of PLGA-PEG nanoparticles across the 
Blood Brain Barrier (BBB). Results of characterization, TEM, SEM images, in vitro drug release 
profiles, stability, cytotoxicity assay, flow cytometry data of uptake of the nanoparticles will be 
presented. 
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